ROS1 gene identified in lung cancer developments

1 February 2012

Lung cancer treatment could be enhanced in the near future, after a new genetic subtype of the disease was identified by researchers.

A team of investigators at the Massachusetts General Hospital (MGH) Cancer Center have conducted a study which concludes that the ROS1 gene represents between one and two per cent of non-small-cell lung cancers.

The research could prove to be a breakthrough for treating this form of cancer, seeing as though the team also disclosed that tumours driven by the ROS1 gene can be fought against using crizotinib treatments.

Alice Shaw, from the MGH Cancer Center, co-authored the paper detailing the study, which can be found in the latest Journal of Clinical Oncology.

Explaining the results, Ms Shaw noted: "This finding is important because we have drugs that inhibit ROS1 and could lead to the sort of dramatic clinical response we describe in this paper."

Details of MGH Cancer Center's research comes soon after experts at Mayo Clinic suggested that obesity and scarring from a hepatitis C infection are now seen as some of the most prevalent causes of liver cancer.

Posted by Jeanette Royston

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)